Catecholamine treatment induces reversible heart injury and cardiomyocyte gene expression.

IF 2.8 Q2 CRITICAL CARE MEDICINE Intensive Care Medicine Experimental Pub Date : 2024-05-11 DOI:10.1186/s40635-024-00632-9
Christine Bode, Sebastian Preissl, Lutz Hein, Achim Lother
{"title":"Catecholamine treatment induces reversible heart injury and cardiomyocyte gene expression.","authors":"Christine Bode, Sebastian Preissl, Lutz Hein, Achim Lother","doi":"10.1186/s40635-024-00632-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Catecholamines are commonly used as therapeutic drugs in intensive care medicine to maintain sufficient organ perfusion during shock. However, excessive or sustained adrenergic activation drives detrimental cardiac remodeling and may lead to heart failure. Whether catecholamine treatment in absence of heart failure causes persistent cardiac injury, is uncertain. In this experimental study, we assessed the course of cardiac remodeling and recovery during and after prolonged catecholamine treatment and investigated the molecular mechanisms involved.</p><p><strong>Results: </strong>C57BL/6N wild-type mice were assigned to 14 days catecholamine treatment with isoprenaline and phenylephrine (IsoPE), treatment with IsoPE and subsequent recovery, or healthy control groups. IsoPE improved left ventricular contractility but caused substantial cardiac fibrosis and hypertrophy. However, after discontinuation of catecholamine treatment, these alterations were largely reversible. To uncover the molecular mechanisms involved, we performed RNA sequencing from isolated cardiomyocyte nuclei. IsoPE treatment resulted in a transient upregulation of genes related to extracellular matrix formation and transforming growth factor signaling. While components of adrenergic receptor signaling were downregulated during catecholamine treatment, we observed an upregulation of endothelin-1 and its receptors in cardiomyocytes, indicating crosstalk between both signaling pathways. To follow this finding, we treated mice with endothelin-1. Compared to IsoPE, treatment with endothelin-1 induced minor but longer lasting changes in cardiomyocyte gene expression. DNA methylation-guided analysis of enhancer regions identified immediate early transcription factors such as AP-1 family members Jun and Fos as key drivers of pathological gene expression following catecholamine treatment.</p><p><strong>Conclusions: </strong>The results from this study show that prolonged catecholamine exposure induces adverse cardiac remodeling and gene expression before the onset of left ventricular dysfunction which has implications for clinical practice. The observed changes depend on the type of stimulus and are largely reversible after discontinuation of catecholamine treatment. Crosstalk with endothelin signaling and the downstream transcription factors identified in this study provide new opportunities for more targeted therapeutic approaches that may help to separate desired from undesired effects of catecholamine treatment.</p>","PeriodicalId":13750,"journal":{"name":"Intensive Care Medicine Experimental","volume":"12 1","pages":"48"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088585/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intensive Care Medicine Experimental","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40635-024-00632-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Catecholamines are commonly used as therapeutic drugs in intensive care medicine to maintain sufficient organ perfusion during shock. However, excessive or sustained adrenergic activation drives detrimental cardiac remodeling and may lead to heart failure. Whether catecholamine treatment in absence of heart failure causes persistent cardiac injury, is uncertain. In this experimental study, we assessed the course of cardiac remodeling and recovery during and after prolonged catecholamine treatment and investigated the molecular mechanisms involved.

Results: C57BL/6N wild-type mice were assigned to 14 days catecholamine treatment with isoprenaline and phenylephrine (IsoPE), treatment with IsoPE and subsequent recovery, or healthy control groups. IsoPE improved left ventricular contractility but caused substantial cardiac fibrosis and hypertrophy. However, after discontinuation of catecholamine treatment, these alterations were largely reversible. To uncover the molecular mechanisms involved, we performed RNA sequencing from isolated cardiomyocyte nuclei. IsoPE treatment resulted in a transient upregulation of genes related to extracellular matrix formation and transforming growth factor signaling. While components of adrenergic receptor signaling were downregulated during catecholamine treatment, we observed an upregulation of endothelin-1 and its receptors in cardiomyocytes, indicating crosstalk between both signaling pathways. To follow this finding, we treated mice with endothelin-1. Compared to IsoPE, treatment with endothelin-1 induced minor but longer lasting changes in cardiomyocyte gene expression. DNA methylation-guided analysis of enhancer regions identified immediate early transcription factors such as AP-1 family members Jun and Fos as key drivers of pathological gene expression following catecholamine treatment.

Conclusions: The results from this study show that prolonged catecholamine exposure induces adverse cardiac remodeling and gene expression before the onset of left ventricular dysfunction which has implications for clinical practice. The observed changes depend on the type of stimulus and are largely reversible after discontinuation of catecholamine treatment. Crosstalk with endothelin signaling and the downstream transcription factors identified in this study provide new opportunities for more targeted therapeutic approaches that may help to separate desired from undesired effects of catecholamine treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿茶酚胺治疗可诱导可逆性心脏损伤和心肌细胞基因表达。
背景:儿茶酚胺是重症监护医学中常用的治疗药物,可在休克期间维持足够的器官灌注。然而,过度或持续的肾上腺素能激活会导致有害的心脏重塑,并可能导致心力衰竭。在没有心力衰竭的情况下,儿茶酚胺治疗是否会导致持续性心脏损伤尚不确定。在这项实验研究中,我们评估了长期儿茶酚胺治疗期间和之后的心脏重塑和恢复过程,并研究了其中的分子机制:结果:C57BL/6N 野生型小鼠被分配到异丙肾上腺素和苯肾上腺素(IsoPE)儿茶酚胺治疗 14 天组、IsoPE 治疗后恢复组或健康对照组。异戊巴比妥可改善左心室收缩力,但会导致大量心脏纤维化和肥大。然而,在停止儿茶酚胺治疗后,这些改变在很大程度上是可逆的。为了揭示其中的分子机制,我们对分离的心肌细胞核进行了 RNA 测序。IsoPE 处理导致与细胞外基质形成和转化生长因子信号转导相关的基因短暂上调。虽然在儿茶酚胺处理过程中肾上腺素能受体信号转导的成分下调,但我们观察到内皮素-1 及其受体在心肌细胞中上调,这表明这两种信号转导途径之间存在串扰。为了跟进这一发现,我们用内皮素-1 治疗小鼠。与 IsoPE 相比,内皮素-1 对心肌细胞基因表达的影响较小,但持续时间更长。对增强子区域的 DNA 甲基化引导分析发现,AP-1 家族成员 Jun 和 Fos 等即刻早期转录因子是儿茶酚胺处理后病理基因表达的主要驱动因素:本研究结果表明,在左心室功能障碍发生之前,长期暴露于儿茶酚胺会诱发不良的心脏重塑和基因表达,这对临床实践具有重要意义。观察到的变化取决于刺激的类型,并且在停止儿茶酚胺治疗后基本上是可逆的。本研究中发现的内皮素信号转导和下游转录因子之间的相互影响为更有针对性的治疗方法提供了新的机会,这可能有助于区分儿茶酚胺治疗的预期效果和不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Intensive Care Medicine Experimental
Intensive Care Medicine Experimental CRITICAL CARE MEDICINE-
CiteScore
5.10
自引率
2.90%
发文量
48
审稿时长
13 weeks
期刊最新文献
Target-controlled dialysis for antibiotics (TCD-ABx). Assessment of mitochondrial function and its prognostic role in sepsis: a literature review. Predictors of intradialytic hypotension in critically ill patients undergoing kidney replacement therapy: a systematic review. Is passive leg raising clinically useful in predicting intradialytic hypotension? Largely ignored-but pathogenetically significant: ambient temperature in rodent sepsis models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1